Cargando…

Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling

BACKGROUND: Sodium glucose cotransporter 2 (SGLT2) inhibitors are newly developed oral antidiabetic drugs. SGLT2 is primarily expressed in the kidneys and reabsorbs approximately 90% of the glucose filtered by the renal glomeruli. SGLT2 inhibitors lower glucose levels independently of insulin action...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suga, Takayoshi, Sato, Ken, Ohyama, Tatsuya, Matsui, Sho, Kobayashi, Takeshi, Tojima, Hiroki, Horiguchi, Norio, Yamazaki, Yuichi, Kakizaki, Satoru, Nishikido, Ayaka, Okamura, Takashi, Yamada, Masanobu, Kitamura, Tadahiro, Uraoka, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Basic Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407917/ https://www.ncbi.nlm.nih.gov/pubmed/32821334 http://dx.doi.org/10.4254/wjh.v12.i7.350

Ejemplares similares

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
por: Sato, Ken, et al.
Publicado: (2022)

Non-invasive prediction of non-alcoholic steatohepatitis in Japanese patients with morbid obesity by artificial intelligence using rule extraction technology
por: Uehara, Daisuke, et al.
Publicado: (2018)

The first reported case of Noonan syndrome complicated with hepatocellular carcinoma
por: Kakizaki, Satoru, et al.
Publicado: (2021)

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
por: Suga, Takayoshi, et al.
Publicado: (2018)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

An Autopsy Case of Multicentric Castleman Disease Presenting with Severe Jaundice
por: Yamazaki, Yuichi, et al.
Publicado: (2021)

Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature
por: Sato, Ken, et al.
Publicado: (2019)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
por: Yamazaki, Yuichi, et al.
Publicado: (2017)

Partial liver irradiation in rats induces the hypertrophy of nonirradiated liver lobes through hepatocyte proliferation(†)
por: Adachi, Takuya, et al.
Publicado: (2023)

Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment
por: Hatanaka, Takeshi, et al.
Publicado: (2020)

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
por: Komiya, Chikara, et al.
Publicado: (2016)

Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice
por: Mori, Kentaro, et al.
Publicado: (2019)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2020)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

Control of Appetite and Food Preference by NMDA Receptor and Its Co-Agonist d-Serine
por: Sasaki, Tsutomu, et al.
Publicado: (2016)

Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately
por: Tojima, Hiroki, et al.
Publicado: (2021)

ODP484 Hyperthyroidism During Prostaglandin I2 Treatment in Pulmonary Hypertension and Its Molecular Mechanism
por: Ishida, Emi, et al.
Publicado: (2022)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

SAT-437 Influence of Smoking on Thyroid Function in Japanese Subjects: Longitudinal Study for One Year of On-Off Smoking
por: Nakajima, Yasuyo, et al.
Publicado: (2020)

A concise and practical stereoselective synthesis of ipragliflozin L-proline
por: Ma, Shuai, et al.
Publicado: (2017)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

Neuronal SIRT1 regulates macronutrient-based diet selection through FGF21 and oxytocin signalling in mice
por: Matsui, Sho, et al.
Publicado: (2018)

Deacetylation of XBP1s by sirtuin 6 confers resistance to ER stress-induced hepatic steatosis
por: Bang, In Hyuk, et al.
Publicado: (2019)

Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study
por: Okada, Junichi, et al.
Publicado: (2020)

Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study
por: Akasaka, Hiroshi, et al.
Publicado: (2022)

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
por: Kutoh, Eiji, et al.
Publicado: (2016)

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
por: Miyake, Teruki, et al.
Publicado: (2018)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Anticancer Agents Targeted to Sirtuins
por: Kozako, Tomohiro, et al.
Publicado: (2014)

ODP297 Analysis of the responsible region of TRH in the hypothalamus-pituitary-thyroid axis using the Paraventricular nucleus-specific TRH deficient mice.
por: Kondo, Yuri, et al.
Publicado: (2022)

CD36/Sirtuin 1 Axis Impairment Contributes to Hepatic Steatosis in ACE2-Deficient Mice
por: Nunes-Souza, Valéria, et al.
Publicado: (2016)

Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α
por: Ren, Huihui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ijs6lvu5c0g9g2lu1o0kdapsc7